BioinvestGPT

BioinvestGPT ApS · Research use only

NCT02831959 (NovoTTF-200M device Best Standard… in Brain Metastases From Non-small Cell Lung…): BVCT ex-ante prediction vs. reported outcome

On 22 Dec 2023, BioinvestGPT's BVCT predicted technical partial success and commercial failure for this trial. The 27 Mar 2024 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically significant yet commercially insufficient (no OS benefit).

Clinical Trial

NCTID
NCT02831959
Acronym
METIS
Drug Name
NovoTTF-200M device Best Standard of Care
Drug MoA
a device delivering low-intensity; wave-like alternating electric fields to the location of the tumor
Drug Modality
medical device
Drug Class
First-In-Class
Therapeutic Area
Neoplasms
Indication
Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
Human Patients
270
Sponsor
NovoCure
Phase
Phase 3

Prediction of , index 984

Prospective Prediction
Prediction Index
984
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient additive clinical benefit)
Technical Prediction
partial SUCCESS (statistically significant yet weak additive clinical benefit)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
96 days in advance
Readout Data Interpretation
21.9month vs 11.3month time to intracranial progression (p=0.016) OS secondary endpoint not met.
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically significant yet commercially insufficient (no OS benefit)
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
Phase
Phase 3
Status
Completed
Enrollment
298
Lead sponsor
NovoCure GmbH
Conditions
Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
Interventions
DEVICE: NovoTTF-200M device; OTHER: Best Standard of Care
Design
Randomized · Parallel · None
Primary purpose
Treatment
Start
2016-07
Primary completion
2024-11-29
Completion
2024-11-29
Primary outcomes
  • Time to intracranial progression (3 years)

NCT02831959 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials